NCT04034121View on ClinicalTrials.gov

Elixir Medical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - Cx Registry

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 20, 2016

Primary Completion Date

January 22, 2017

Study Completion Date

September 30, 2020

Conditions
Coronary Artery Disease
Interventions
DEVICE

DESolve Cx drug eluting coronary scaffold system

percutaneous coronary intervention

Trial Locations (3)

2020

AZ Middelheim Hospital, Antwerp

B-3600

St. - Jan Ziekenhuis Z.O.L., Genk

0401210

Instituto Dante Pazzanese, São Paulo

Sponsors
All Listed Sponsors
lead

Elixir Medical Corporation

INDUSTRY

NCT04034121 - Elixir Medical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - Cx Registry | Biotech Hunter | Biotech Hunter